EYET Eyetech Pharmaceuticals (MM)

Eyetech to Present at Morgan Stanley's Third Annual Global Healthcare Unplugged Conference NEW YORK, April 21 /PRNewswire-FirstCall/ -- Eyetech Pharmaceuticals, Inc. (NASDAQ:EYET) today announced that it will present at Morgan Stanley's Third Annual Healthcare Unplugged Conference in Miami, Florida on Thursday, May 5, 2005 at 9:30 a.m. Eastern Time. (Logo: http://www.newscom.com/cgi-bin/prnh/20050407/EYETLOGO ) Interested parties may access a live audio webcast of the presentation by logging on to the Investor Relations section of our corporate website at http://www.eyetech.com/. An archived version of the webcast will be available at both locations through May 12, 2005. About Eyetech Pharmaceuticals, Inc. Eyetech Pharmaceuticals, Inc. is a biopharmaceutical company that specializes in the development and commercialization of novel therapeutics to treat diseases of the eye. Eyetech's initial focus is on diseases affecting the back of the eye. Eyetech is commercializing and further developing Macugen(R) (pegaptanib sodium injection) with Pfizer Inc for the treatment of neovascular AMD. Macugen is also being studied for the treatment of diabetic macular edema and retinal vein occlusion. http://www.newscom.com/cgi-bin/prnh/20050407/EYETLOGODATASOURCE: Eyetech Pharmaceuticals, Inc. CONTACT: Investors, Glenn Sblendorio, Chief Financial Officer, +1-212-824-3100, or fax, +1-212-824-3240, ; or Media, Chris Smith, Public Relations & Corporate Communications, +1-212-824-3203, or fax, +1-212-824-3240, , both of Eyetech Pharmaceuticals Web site: http://www.eyetk.com/

Copyright